Biodesign startup OncoMyx Therapeutics, Inc. receives Fast Lane Award from AZBio

Biodesign startup OncoMyx Therapeutics, Inc. receives Fast Lane Award from AZBio

October 15, 2019

  • Grant McFadden

    Grant McFadden, director of the Biodesign Center for Immunotherapy, Vaccines and Virotherapy, and co-founder of OncoMyx


    Download Photo
  • Grant McFadden

    OncoMyx will spearhead the next-stage development plans of oncolytic myxoma virus to seek FDA approval and conduct the first human clinical trials, using their patented systemic delivery approach.


    Download Photo

October 15, 2019

The Arizona Bioindustry Association (AZBio) named OncoMyx Therapeutics, Inc.,  an Arizona State University Biodesign Institute startup, as a Fast Lane Company for 2019. Other Arizona companies to receive the distinction during Arizona Biosciences Week this year were Biosensing Instrument, Tempe, Arizona, and Gt Medical Technologies, Mesa, Arizona.

The annual award recognizes Arizona bioscience companies that have arrived at significant milestones during the past 18 months. Impact is measured by such factors as clinical results, regulatory approvals, certifications, collaborations, funding awards, product launches, job growth or product sales milestones.

OncoMyx was incorporated in 2018 by founders Grant McFadden, director of the Biodesign Center for Immunotherapy, Vaccines and Virotherapy, company CEO Steve Potts and COO Michael Wood. The company aims “to develop oncolytic immunotherapies with an unambiguous, promotable advantage that eradicate hard-to-cure cancers.”

The company is creating tumor-destroying immunotherapies based on the myxoma virus (MYXV), a poxvirus that causes localized skin infections in rabbits, but is safe in humans and any organism outside of rabbits. The virus has a unique ability to be carried systemically by human leukocytes where it can then infect tumor cells. McFadden has pioneered the MYXV field and is widely regarded as a top oncolytic virus (OV) expert.

McFadden and his collaborators have spent the past two decades evaluating MYXV in a wide variety of tumor models. The natural target of the virus is the European rabbit, in which it causes a lethal disease. Because it only grows in rabbit cells or cancer cells, it does not infect healthy human tissue. In humans, the virus is harmless, except when it encounters a cancer cell. McFadden’s research team has successfully targeted various types of cancers.

According to McFadden, “OVs are emerging as a new pillar of cancer care to complement the effectiveness of immunotherapies such as immune checkpoint blockade. The best-in-class MYXV platform is the only OV in development that is collectively a non-human pathogen, inherently immuno-stimulatory, easily multi-armed, and systemically delivered.”

In June 2019, OncoMyx announced the completion of a $25 million series A financing led by Boehringer Ingelheim Venture Fund (BIVF), Delos Capital, and Xeraya Capital with participation from Korea Investment Partners (KIP), City Hill Ventures, and Madison Partners. OncoMyx is using the proceeds to advance development of its lead oncolytic virus therapeutic program for the treatment of various cancers.

OncoMyx is currently being launched in Phoenix to test next-generation viruses in human clinical trials against a variety of human cancers.

OncoMyx will spearhead the next-stage development plans of oncolytic myxoma virus to seek FDA approval and conduct the first human clinical trials, using their patented systemic delivery approach. The company will capitalize on McFadden’s two decades of research into the potential of oncolytic viruses. McFadden sequenced the myxoma virus genome in 1999, and since then has produced dozens of genetically engineered constructs, demonstrating its ability as an oncolytic agent across many tumors in preclinical cell and animal models.

Preclinical studies in mice and testing on cancer patient samples from Mayo Clinic in Scottsdale have demonstrated encouraging immune responses against tumors. These data points build upon the continued clinical validation of OncoMyx’s platform to expand the boundaries of cancer treatment and potentially benefit a large group of patients.

Dr. Kanad Das, Executive Director of Boehringer Ingelheim Venture Fund. “We look forward to working with the team to develop drugs that help improve patients’ lives across a range of malignancies.”

For more information about Grant McFadden and his work with the rabbit virus, visit “Treating Cancer with a Rabbit Trick" at Ask a Biologist.

 

Written by: Dianne Price